Biologic therapy for acrodermatitis continua of Hallopeau: Successful treatment with secukinumab and review of the literature. Issue 3 (29th April 2019)

• Record Type: Journal Article
• Authors: Galluzzo, Marco; D'Adamio, Simone; Teoli, Miriam; Bianchi, Luca; Talamonti, Marina
• Is Part Of: Dermatologic therapy. Volume 32:Issue 3(2019)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2019-04-29
• Subjects: acrodermatitis continua of Hallopeau -- psoriasis -- psoriatic arthritis -- secukinumab; Skin -- Diseases -- Periodicals; Dermatology -- Periodicals; 616.5
• DOI: 10.1111/dth.12899
• Languages: English
• ISSNs: 1396-0296

Abstract

Abstract: Acrodermatitis continua of Hallopeau (ACH) is a rare pustular psoriasis variant refractory to many conventional treatments. We report the successful treatment with secukinumab of a patient with a long history of ACH with marked onychodystrophy with frank pustulosis on the nail bed and with accompanying arthritis. Blockade of the IL‐17 receptor A has shown promise in the treatment of psoriatic erythroderma and generalized pustular psoriasis not responsive to conventional treatment. A rapid response was observed in our patient, in both skin lesions and arthritic symptoms, underlining the ability of secukinumab to improve symptoms beyond those of plaque psoriasis.